Those who taking semaglutide to treat obesity were more than seven times more likely to receive a diagnosis
The abdomen is a favorable location due to its ample surface area and presence of uniform subcutaneous fat, resulting in dependable absorption
Past research on tirzepatide found participants who took a higher dosage lost more than 22% of their body weight over 16 months
[1] [4] In the SURMOUNT-1 clinical trial, patients taking Zepbound achieved substantial weight lossaveraging 15-21% of body weight over 72 weeksprimarily through reduced caloric intake
However, the ADA notes that long-term offspring outcomes remain uncertain
Clinical Considerations Disease Associated Maternal and Fetal Risk: Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery and delivery complications